Inhibition of GSK-3beta activity with the GSK3beta inhibitors SB-216763 and AR-A014418 controled cancer cell survival and proliferation, in a manner unrelated to Wnt/beta-catenin signaling and Akt activation, through decreasing telomerase reverse transcriptase (hTERT) expression and telomerase activity [256]. This evidence concerns the gene GSK3B and cancer.